
Dr. Reddy's Laboratories has kicked off FY25 with a strong performance, reflecting its strategic focus on diversified growth and long-term sustainability. The company's Q1FY25 earnings, announced on July 27, 2024, revealed a double-digit revenue growth, stable EBITDA margins, and a clear roadmap for future growth across multiple business segments.
A Robust Start to FY25